Top

Published in:

Open Access 01-01-2024 | Nausea | Special Section

2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting

Authors: Bernardo Leon Rapoport, Jørn Herrstedt, Rebecca Clark Snow, Venkatraman Radhakrishnan, Mitsue Saito, Rudolph M. Navari, Teresa Smit

Published in: Supportive Care in Cancer | Issue 1/2024

Abstract

Purpose

This review is an update of the MASCC/ESMO 2015 recommendations for the prophylaxis of acute and delayed nausea and vomiting induced by multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.

Methods

A systematic literature search was conducted using PubMed from June 1, 2015, through February 1, 2023.

Results

We identified 56 references (16 were duplications or invalid), leaving 40 manuscripts for this search. The panel classified level I evidence (three manuscripts) and level II evidence (14 manuscripts). High-dose chemotherapy and stem cell transplant were discussed in four of these manuscripts, and multiple-day chemotherapy treatment in 15. Some manuscripts covered both topics. Additionally, a search for breakthrough nausea and vomiting resulted in 12 “hits.” No new relevant studies were identified.

Conclusions

The recommendations for patients receiving high-dose chemotherapy with stem cell transplants and patients undergoing multiple-day cisplatin were updated. For patients receiving high-dose chemotherapy for stem cell transplant, a combination of a 5-HT₃ receptor antagonist with dexamethasone and aprepitant is recommended. Olanzapine could be considered part of the antiemetic regimen. Patients receiving multiple-day cisplatin should receive a 5-HT₃ receptor antagonist plus dexamethasone plus aprepitant plus olanzapine. For patients experiencing breakthrough nausea and vomiting, the available evidence suggests using a single dose of olanzapine daily for 3 days.

Einhorn LH, Rapoport B, Navari RM, Herrstedt J, Brames MJ (2017) 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 25:303–308. https://doi.org/10.1007/s00520-016-3449-yCrossRefPubMed

Di Renzo N, Musso M, Scimè R (2022) Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin’s lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation. Support Care Cancer 30:1521–1527. https://doi.org/10.1007/s00520-021-06495-0CrossRefPubMed

Nakagaki M, Barras M, Curley C et al (2017) A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation. Support Care Cancer 25:607–613. https://doi.org/10.1007/s00520-016-3445-2CrossRefPubMed

Clemmons AB, Orr BA, Arpita G et al (2018) Randomized, placebo-controlled, phase III trial of fosaprepitant, ondansetron, dexamethasone (FOND) versus FOND plus olanzapine (FOND-O) for the prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies receiving highly emetogenic chemotherapy and hematopoietic cell transplantation regimens: the FOND-O trial. Biol Blood Marrow Transplant 24:2065–2071. https://doi.org/10.1016/j.bbmt.2018.06.005CrossRefPubMed

Trifilio S, Welles C, Seeger K et al (2017) Olanzapine reduces chemotherapy-induced nausea and vomiting compared with aprepitant in myeloma patients receiving high-dose melphalan before stem cell transplantation: a retrospective study. Clin Lymphoma Myeloma Leukemia 17:584–589. https://doi.org/10.1016/j.clml.2017.06.012CrossRef

Isoda A, Saito R, Komatsu F et al (2017) Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: A phase II study. Clinical Trial Int J Hematol 105:478–484. https://doi.org/10.1007/s12185-016-2152-6CrossRefPubMed

Bubalo J, Mulverhill K, Meyers G et al (2018) A randomized, placebo-controlled pilot trial of aprepitant combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients undergoing cyclophosphamide-based conditioning regimens before hematopoietic stem cell transplant (HSCT). Bone Marrow Transplant 53:1010–1018. https://doi.org/10.1038/s41409-018-0106-8CrossRefPubMed

Zhao Y, Yang Y, Gao F, Hu C, Zhong D, Lu M, Yuan Z, Zhao J, Miao J, Li Y, Zhu J, Wang C, Han J, Zhao Y, Huang Y, Zhang L (2022) A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study). EClinicalMedicine 55:101771. https://doi.org/10.1016/j.eclinm.2022.101771CrossRefPubMedPubMedCentral

Liu G, Jin Y, Jiang Y, Zhao J, Jiang C, Zhang Z, Zhao L, Li H, Chen F, Wang J, Fan H, Li Z, Jia Y, Jin G, Li Q (2022) A comparison of the efficacy of 5 mg olanzapine and aprepitant in the prevention of multiple-day cisplatin chemotherapy-induced nausea and vomiting. Int J Clin Pract 5954379. https://doi.org/10.1155/2022/5954379

10.

Badalamenti G, Incorvaia L, Messina C, Musso E, Casarin A, Ricciardi MR, De Luca I, Bazan V, Russo A (2019) One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients. Support Care Cancer 27:3593–3597. https://doi.org/10.1007/s00520-019-4645-3CrossRefPubMedPubMedCentral

11.

Di Renzo N, Melillo L, Porretto F, Dargenio M, Pavone V, Pastore D, Mazza P, Mannina D, Merenda A, Cascavilla N, Greco G, Matera R, Bonizzoni E, Celio L, Musso M (2020) Every-other-day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: a randomized, controlled study from the “Rete Ematologica Pugliese.” Cancer Med 9:170–178. https://doi.org/10.1002/cam4.2628CrossRefPubMed

12.

Li Q, Wu Y, Wang W, Deng S, Jiang C, Chen F, Zhao J, Li H, Bai X, Hou J, Da L, Zhao L, Gao J, Jin G (2019) Effectiveness and safety of combined neurokinin-1 antagonist aprepitant treatment for multiple-day anthracycline-induced nausea and vomiting. Curr Probl Cancer 43:100462. https://doi.org/10.1016/j.currproblcancer.2019.01.003CrossRefPubMed

13.

Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94:1011–1015. https://doi.org/10.1038/sj.bjc.6603048CrossRefPubMedPubMedCentral

14.

Tamura K, Aiba K, Saeki T et al (2017) Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan. Int J Clin Oncol 22:405–412. https://doi.org/10.1007/s10147-016-1069-7CrossRefPubMed

15.

Molassiotis A, Aapro M, Dicato M, Gascon P, Novoa SA, Isambert N, Burke TA, Gu A, Roila F (2014) Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manage 47:839-848.e4. https://doi.org/10.1016/j.jpainsymman.2013.06.012CrossRefPubMed

16.

Maeda A, Yoshida H, Inoue H et al (2021) Effects of 5-mg dose of olanzapine for breakthrough nausea and vomiting in patients receiving carboplatin-based chemotherapy: a prospective trial. Ann Palliat Med 10:2699–2708. https://doi.org/10.21037/apm-20-1784CrossRefPubMed

17.

Chiu L, Chow R, Popovic M et al (2016) Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Support Care Cancer 24:2381–2392. https://doi.org/10.1007/s00520-016-3075-8CrossRefPubMed

18.

Inoue T, Kimura M, Uchida J et al (2017) Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Clin Trial Int J Clin Oncol 22:600–604. https://doi.org/10.1007/s10147-016-1081-yCrossRefPubMed

Title: 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting
Authors: Bernardo Leon Rapoport
Jørn Herrstedt
Rebecca Clark Snow
Venkatraman Radhakrishnan
Mitsue Saito
Rudolph M. Navari
Teresa Smit
Publication date: 01-01-2024
Publisher: Springer Berlin Heidelberg
Keywords: Nausea
Olanzapine
Cytostatic Therapy
Vomiting
Dexamethasone
Stem Cell Transplantation
Stem Cell Transplantion
Stem Cell Transplantation
Published in: Supportive Care in Cancer / Issue 1/2024
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-023-08224-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Trend analysis of quality indicators in palliative home care among terminally ill cancer and non-cancer patients in Taiwan: a 6-year observational study

Correction to: Abstracts for MASCC/JASCC/ISOO Annual Meeting 2023

Effects of pulmonary rehabilitation in hematopoietic stem cell transplantation recipients: a randomized controlled study

Evaluating a shared care pathway intervention for people receiving chemotherapy to reduce post-treatment unplanned hospital presentations: a randomised controlled trial

2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents

Patterns and influencing factors of exercise attendance of breast cancer patients during neoadjuvant chemotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer